Wednesday, 18 Nov 2026

Empowering Chinese Pharma’s Global Expansion

Contact US
Insight,  China's Pharmaceutical Industry
  • Home
  • About US
  • Policy Hub
  • Categories
    • Drug
    • Company
    • Deals
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Legal / IP
    • Digital
  • Privacy Policy
  • Contact US
My News
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
Insight,  China's Pharmaceutical IndustryInsight,  China's Pharmaceutical Industry
  • Read History
Search
  • Pages
    • Home
    • Blog Index
    • POLICY HUB
    • Contact Us
  • Personalized
    • Read History
  • Categories
    • Company
    • Drug
    • Policy / Regulatory
    • Medical Device
    • R&D
    • Digital
    • Legal / IP
    • Deals
Have an existing account? Sign In
Follow US

BOM: 543904

  • #
  • Cancer
  • Clinical trial approval / initiation
  • Product approvals
  • Clinical trial results
  • Finance
  • ADC / XDC
  • Finanical Reports
  • Biotech
  • Market approval filings
  • PD-1/L1
  • Rare / orphan disease drugs
  • Auto-immune
  • Vaccine
  • Cell-therapy
  • Multi-specific antibodies
  • CVD
  • AstraZeneca
  • Hengrui Pharmaceuticals
  • SHA: 600276
  • Diabetes
Betta Pharmaceuticals Licenses Next‑Generation ALK Inhibitor Ensartinib to Mankind Pharma for India – Upfront, Milestones and Tiered Royalties in Exclusive Territory Deal
CompanyDeals

Betta Pharmaceuticals Licenses Next‑Generation ALK Inhibitor Ensartinib to Mankind Pharma for India – Upfront, Milestones and Tiered Royalties in Exclusive Territory Deal

Betta Pharmaceuticals (SHE: 300558) announced that it has entered into a licensing agreement with leading Indian pharmaceutical company Mankind Pharma (BOM: 543904; NSE: MANKIND), granting Mankind exclusive rights to ensartinib…

November 17, 2026
Simcere Pharmaceutical's SIM0712 Wins NMPA IND Approval for Atopic Dermatitis Trials – Oral STAT6 PROTAC Degrader Taps Type 2 Inflammation Pathway

Simcere Pharmaceutical’s SIM0712 Wins NMPA IND Approval for Atopic Dermatitis Trials – Oral STAT6 PROTAC Degrader Taps Type 2 Inflammation Pathway

November 17, 2026
Stipple Bio Signs Multi‑Target, Multi‑Modality Research Collaboration with Eli Lilly – Pointillist Platform Deal Carries Up to USD 5.9 Billion in Milestones

Stipple Bio Signs Multi‑Target, Multi‑Modality Research Collaboration with Eli Lilly – Pointillist Platform Deal Carries Up to USD 5.9 Billion in Milestones

November 17, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Insight,  China's Pharmaceutical Industry

Information You Can Trust: Stay instantly connected with breaking stories and live updates. From politics and technology to entertainment and beyond, we provide real-time coverage you can rely on, making us your dependable source for 24/7 news.

Youtube Medium Rss

About Company

  • Contact Us
  • Advertise with US
  • Complaint
  • Our Team
  • Our Values
  • Privacy Policy
Subscribe Now for Real-time Updates on the Latest Stories!

© 2026 Fineline Information & Technology. Independent intelligence on China’s pharmaceutical industry.  All Rights Reserved.

Fineline Information & Technology
Welcome to Fineline Cube!
Username or Email Address
Password

Lost your password?

Not a member? Sign Up